Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia

The clinical characteristics and optimal duration of corticosteroid treatment for acute eosinophilic pneumonia (AEP) have not been fully evaluated. This was a retrospective study of prospectively collected data from 137 patients with AEP, treated with standardised protocol, to clarify the clinical c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The European respiratory journal 2013-02, Vol.41 (2), p.402-409
Hauptverfasser: CHIN KOOK RHEE, KYUNG HOON MIN, NAM YEOL YIM, JI EUN LEE, NA RAE LEE, MAN PYO CHUNG, JEON, Kyeongman
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 409
container_issue 2
container_start_page 402
container_title The European respiratory journal
container_volume 41
creator CHIN KOOK RHEE
KYUNG HOON MIN
NAM YEOL YIM
JI EUN LEE
NA RAE LEE
MAN PYO CHUNG
JEON, Kyeongman
description The clinical characteristics and optimal duration of corticosteroid treatment for acute eosinophilic pneumonia (AEP) have not been fully evaluated. This was a retrospective study of prospectively collected data from 137 patients with AEP, treated with standardised protocol, to clarify the clinical characteristics and compare the efficacies of 2 weeks versus 4 weeks of corticosteroid treatment for AEP. The majority of the patients altered their smoking habits within a median (interquartile range) of 17 (13-26) days prior to development of AEP. 80 (58%) patients presented with acute respiratory failure. A total of 127 (92%) patients were treated with corticosteroids: 4 weeks, n=42; 2 weeks, n=85. Major symptoms were resolved in 3 days and the severity of respiratory failure was inversely correlated with clinical outcomes. After adjusting for differences in baseline characteristics between the groups, the differences in adjusted mean (95% confidence interval) for resolution of dyspnoea and disappearance of all symptoms were 0.57 (-0.71-1.86) and -0.04 (-1.91-1.83) days, respectively. The difference in adjusted proportion of resolution of radiological abnormalities was 6.92% (-8.19-22.02). In conclusion, the duration of corticosteroid treatment could be shortened to 2 weeks, even in patients with respiratory failure.
doi_str_mv 10.1183/09031936.00221811
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1283727001</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1283727001</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-1c35eff756ec4f05f25282ec68c9fe9f0f36f39088335b40f1ce37d03d793e9c3</originalsourceid><addsrcrecordid>eNpFkE1PwzAMhiMEYmPwA7igXpC4FJK4aZMjmviSkLiwc5W5jhbUNiNpD_x7Om2Dky37eS35Yexa8HshNDxww0EYKO85l1JoIU7YXIAxOXAOp2y-2-c7YMYuUvriXJQFiHM2k1IZA8rM2WrZ-t6jbTPc2GhxoOjT4DFltm8yDHHqQ5qmwTfZEMkOHfVDFlxmcRwoo5B8H7Yb33rMtj2NXei9vWRnzraJrg51wVbPT5_L1_z94-Vt-fieY1HwIRcIipyrVElYOK6cVFJLwlKjcWQcd1A6MFxrALUuuBNIUDUcmsoAGYQFu9vf3cbwPVIa6s4npLa1PYUx1UJqqGQ1PT6hYo9iDClFcvU2-s7Gn1rwemezPtqsjzanzM3h_LjuqPlLHPVNwO0BsGly6KLt0ad_rtS6VKqAX083fVU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1283727001</pqid></control><display><type>article</type><title>Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>CHIN KOOK RHEE ; KYUNG HOON MIN ; NAM YEOL YIM ; JI EUN LEE ; NA RAE LEE ; MAN PYO CHUNG ; JEON, Kyeongman</creator><creatorcontrib>CHIN KOOK RHEE ; KYUNG HOON MIN ; NAM YEOL YIM ; JI EUN LEE ; NA RAE LEE ; MAN PYO CHUNG ; JEON, Kyeongman</creatorcontrib><description>The clinical characteristics and optimal duration of corticosteroid treatment for acute eosinophilic pneumonia (AEP) have not been fully evaluated. This was a retrospective study of prospectively collected data from 137 patients with AEP, treated with standardised protocol, to clarify the clinical characteristics and compare the efficacies of 2 weeks versus 4 weeks of corticosteroid treatment for AEP. The majority of the patients altered their smoking habits within a median (interquartile range) of 17 (13-26) days prior to development of AEP. 80 (58%) patients presented with acute respiratory failure. A total of 127 (92%) patients were treated with corticosteroids: 4 weeks, n=42; 2 weeks, n=85. Major symptoms were resolved in 3 days and the severity of respiratory failure was inversely correlated with clinical outcomes. After adjusting for differences in baseline characteristics between the groups, the differences in adjusted mean (95% confidence interval) for resolution of dyspnoea and disappearance of all symptoms were 0.57 (-0.71-1.86) and -0.04 (-1.91-1.83) days, respectively. The difference in adjusted proportion of resolution of radiological abnormalities was 6.92% (-8.19-22.02). In conclusion, the duration of corticosteroid treatment could be shortened to 2 weeks, even in patients with respiratory failure.</description><identifier>ISSN: 0903-1936</identifier><identifier>EISSN: 1399-3003</identifier><identifier>DOI: 10.1183/09031936.00221811</identifier><identifier>PMID: 22599359</identifier><language>eng</language><publisher>Leeds: Maney</publisher><subject>Acute Disease ; Adrenal Cortex Hormones - therapeutic use ; Biological and medical sciences ; Bones, joints and connective tissue. Antiinflammatory agents ; Drug Administration Schedule ; Humans ; Male ; Medical sciences ; Pharmacology. Drug treatments ; Pneumology ; Pulmonary Eosinophilia - drug therapy ; Respiratory system : syndromes and miscellaneous diseases ; Retrospective Studies ; Smoking - adverse effects ; Tobacco, tobacco smoking ; Toxicology ; Treatment Outcome ; Young Adult</subject><ispartof>The European respiratory journal, 2013-02, Vol.41 (2), p.402-409</ispartof><rights>2014 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-1c35eff756ec4f05f25282ec68c9fe9f0f36f39088335b40f1ce37d03d793e9c3</citedby><cites>FETCH-LOGICAL-c440t-1c35eff756ec4f05f25282ec68c9fe9f0f36f39088335b40f1ce37d03d793e9c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=26886554$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22599359$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CHIN KOOK RHEE</creatorcontrib><creatorcontrib>KYUNG HOON MIN</creatorcontrib><creatorcontrib>NAM YEOL YIM</creatorcontrib><creatorcontrib>JI EUN LEE</creatorcontrib><creatorcontrib>NA RAE LEE</creatorcontrib><creatorcontrib>MAN PYO CHUNG</creatorcontrib><creatorcontrib>JEON, Kyeongman</creatorcontrib><title>Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia</title><title>The European respiratory journal</title><addtitle>Eur Respir J</addtitle><description>The clinical characteristics and optimal duration of corticosteroid treatment for acute eosinophilic pneumonia (AEP) have not been fully evaluated. This was a retrospective study of prospectively collected data from 137 patients with AEP, treated with standardised protocol, to clarify the clinical characteristics and compare the efficacies of 2 weeks versus 4 weeks of corticosteroid treatment for AEP. The majority of the patients altered their smoking habits within a median (interquartile range) of 17 (13-26) days prior to development of AEP. 80 (58%) patients presented with acute respiratory failure. A total of 127 (92%) patients were treated with corticosteroids: 4 weeks, n=42; 2 weeks, n=85. Major symptoms were resolved in 3 days and the severity of respiratory failure was inversely correlated with clinical outcomes. After adjusting for differences in baseline characteristics between the groups, the differences in adjusted mean (95% confidence interval) for resolution of dyspnoea and disappearance of all symptoms were 0.57 (-0.71-1.86) and -0.04 (-1.91-1.83) days, respectively. The difference in adjusted proportion of resolution of radiological abnormalities was 6.92% (-8.19-22.02). In conclusion, the duration of corticosteroid treatment could be shortened to 2 weeks, even in patients with respiratory failure.</description><subject>Acute Disease</subject><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Bones, joints and connective tissue. Antiinflammatory agents</subject><subject>Drug Administration Schedule</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Pneumology</subject><subject>Pulmonary Eosinophilia - drug therapy</subject><subject>Respiratory system : syndromes and miscellaneous diseases</subject><subject>Retrospective Studies</subject><subject>Smoking - adverse effects</subject><subject>Tobacco, tobacco smoking</subject><subject>Toxicology</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0903-1936</issn><issn>1399-3003</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1PwzAMhiMEYmPwA7igXpC4FJK4aZMjmviSkLiwc5W5jhbUNiNpD_x7Om2Dky37eS35Yexa8HshNDxww0EYKO85l1JoIU7YXIAxOXAOp2y-2-c7YMYuUvriXJQFiHM2k1IZA8rM2WrZ-t6jbTPc2GhxoOjT4DFltm8yDHHqQ5qmwTfZEMkOHfVDFlxmcRwoo5B8H7Yb33rMtj2NXei9vWRnzraJrg51wVbPT5_L1_z94-Vt-fieY1HwIRcIipyrVElYOK6cVFJLwlKjcWQcd1A6MFxrALUuuBNIUDUcmsoAGYQFu9vf3cbwPVIa6s4npLa1PYUx1UJqqGQ1PT6hYo9iDClFcvU2-s7Gn1rwemezPtqsjzanzM3h_LjuqPlLHPVNwO0BsGly6KLt0ad_rtS6VKqAX083fVU</recordid><startdate>20130201</startdate><enddate>20130201</enddate><creator>CHIN KOOK RHEE</creator><creator>KYUNG HOON MIN</creator><creator>NAM YEOL YIM</creator><creator>JI EUN LEE</creator><creator>NA RAE LEE</creator><creator>MAN PYO CHUNG</creator><creator>JEON, Kyeongman</creator><general>Maney</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130201</creationdate><title>Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia</title><author>CHIN KOOK RHEE ; KYUNG HOON MIN ; NAM YEOL YIM ; JI EUN LEE ; NA RAE LEE ; MAN PYO CHUNG ; JEON, Kyeongman</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-1c35eff756ec4f05f25282ec68c9fe9f0f36f39088335b40f1ce37d03d793e9c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Acute Disease</topic><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Bones, joints and connective tissue. Antiinflammatory agents</topic><topic>Drug Administration Schedule</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Pneumology</topic><topic>Pulmonary Eosinophilia - drug therapy</topic><topic>Respiratory system : syndromes and miscellaneous diseases</topic><topic>Retrospective Studies</topic><topic>Smoking - adverse effects</topic><topic>Tobacco, tobacco smoking</topic><topic>Toxicology</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CHIN KOOK RHEE</creatorcontrib><creatorcontrib>KYUNG HOON MIN</creatorcontrib><creatorcontrib>NAM YEOL YIM</creatorcontrib><creatorcontrib>JI EUN LEE</creatorcontrib><creatorcontrib>NA RAE LEE</creatorcontrib><creatorcontrib>MAN PYO CHUNG</creatorcontrib><creatorcontrib>JEON, Kyeongman</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The European respiratory journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CHIN KOOK RHEE</au><au>KYUNG HOON MIN</au><au>NAM YEOL YIM</au><au>JI EUN LEE</au><au>NA RAE LEE</au><au>MAN PYO CHUNG</au><au>JEON, Kyeongman</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia</atitle><jtitle>The European respiratory journal</jtitle><addtitle>Eur Respir J</addtitle><date>2013-02-01</date><risdate>2013</risdate><volume>41</volume><issue>2</issue><spage>402</spage><epage>409</epage><pages>402-409</pages><issn>0903-1936</issn><eissn>1399-3003</eissn><abstract>The clinical characteristics and optimal duration of corticosteroid treatment for acute eosinophilic pneumonia (AEP) have not been fully evaluated. This was a retrospective study of prospectively collected data from 137 patients with AEP, treated with standardised protocol, to clarify the clinical characteristics and compare the efficacies of 2 weeks versus 4 weeks of corticosteroid treatment for AEP. The majority of the patients altered their smoking habits within a median (interquartile range) of 17 (13-26) days prior to development of AEP. 80 (58%) patients presented with acute respiratory failure. A total of 127 (92%) patients were treated with corticosteroids: 4 weeks, n=42; 2 weeks, n=85. Major symptoms were resolved in 3 days and the severity of respiratory failure was inversely correlated with clinical outcomes. After adjusting for differences in baseline characteristics between the groups, the differences in adjusted mean (95% confidence interval) for resolution of dyspnoea and disappearance of all symptoms were 0.57 (-0.71-1.86) and -0.04 (-1.91-1.83) days, respectively. The difference in adjusted proportion of resolution of radiological abnormalities was 6.92% (-8.19-22.02). In conclusion, the duration of corticosteroid treatment could be shortened to 2 weeks, even in patients with respiratory failure.</abstract><cop>Leeds</cop><pub>Maney</pub><pmid>22599359</pmid><doi>10.1183/09031936.00221811</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0903-1936
ispartof The European respiratory journal, 2013-02, Vol.41 (2), p.402-409
issn 0903-1936
1399-3003
language eng
recordid cdi_proquest_miscellaneous_1283727001
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Acute Disease
Adrenal Cortex Hormones - therapeutic use
Biological and medical sciences
Bones, joints and connective tissue. Antiinflammatory agents
Drug Administration Schedule
Humans
Male
Medical sciences
Pharmacology. Drug treatments
Pneumology
Pulmonary Eosinophilia - drug therapy
Respiratory system : syndromes and miscellaneous diseases
Retrospective Studies
Smoking - adverse effects
Tobacco, tobacco smoking
Toxicology
Treatment Outcome
Young Adult
title Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T05%3A56%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20characteristics%20and%20corticosteroid%20treatment%20of%20acute%20eosinophilic%20pneumonia&rft.jtitle=The%20European%20respiratory%20journal&rft.au=CHIN%20KOOK%20RHEE&rft.date=2013-02-01&rft.volume=41&rft.issue=2&rft.spage=402&rft.epage=409&rft.pages=402-409&rft.issn=0903-1936&rft.eissn=1399-3003&rft_id=info:doi/10.1183/09031936.00221811&rft_dat=%3Cproquest_cross%3E1283727001%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1283727001&rft_id=info:pmid/22599359&rfr_iscdi=true